Danielle Antalffy
Stock Analyst at UBS
(3.45)
# 881
Out of 5,172 analysts
205
Total ratings
45.76%
Success rate
4.77%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $120 → $105 | $69.48 | +51.12% | 16 | Mar 17, 2026 | |
| SYK Stryker | Maintains: Neutral | $400 → $380 | $335.67 | +13.21% | 8 | Mar 17, 2026 | |
| SGHT Sight Sciences | Maintains: Buy | $12 → $11 | $3.47 | +217.00% | 4 | Mar 6, 2026 | |
| RXST RxSight | Maintains: Neutral | $8 → $9 | $6.44 | +39.75% | 5 | Feb 26, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $17 → $22 | $24.82 | -11.36% | 16 | Feb 20, 2026 | |
| ATRC AtriCure | Maintains: Buy | $60 → $55 | $29.18 | +88.52% | 14 | Feb 18, 2026 | |
| ZBH Zimmer Biomet Holdings | Maintains: Sell | $88 → $86 | $87.87 | -2.13% | 7 | Jan 28, 2026 | |
| EW Edwards Lifesciences | Maintains: Neutral | $92 → $95 | $82.50 | +15.15% | 14 | Jan 12, 2026 | |
| INSP Inspire Medical Systems | Maintains: Neutral | $89 → $91 | $53.72 | +69.40% | 8 | Dec 23, 2025 | |
| GKOS Glaukos | Maintains: Buy | $140 → $145 | $100.99 | +43.58% | 3 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $62 | $25.79 | +140.40% | 4 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $102 | $86.16 | +18.38% | 12 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $355 → $400 | $227.10 | +76.13% | 13 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.5 → $5.85 | $1.24 | +371.77% | 8 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $16 | $13.53 | +18.26% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $95 | $66.95 | +41.90% | 10 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $21 | $16.15 | +30.03% | 7 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $585 → $600 | $477.97 | +25.53% | 3 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $190 → $214 | $235.37 | -9.08% | 6 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $57 | $21.85 | +160.87% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $146 → $148 | $105.46 | +40.34% | 12 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $3.97 | -43.32% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $3.36 | +24,453.57% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $30.78 | -54.52% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $76.43 | +30.84% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $13.00 | -7.69% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $31.41 | +43.27% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $154.13 | +78.42% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.39 | +736.82% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.10 | +588.52% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $60 | $6.48 | +825.93% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.66 | +2,172.73% | 1 | Sep 1, 2020 |
Boston Scientific
Mar 17, 2026
Maintains: Buy
Price Target: $120 → $105
Current: $69.48
Upside: +51.12%
Stryker
Mar 17, 2026
Maintains: Neutral
Price Target: $400 → $380
Current: $335.67
Upside: +13.21%
Sight Sciences
Mar 6, 2026
Maintains: Buy
Price Target: $12 → $11
Current: $3.47
Upside: +217.00%
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $8 → $9
Current: $6.44
Upside: +39.75%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $17 → $22
Current: $24.82
Upside: -11.36%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $60 → $55
Current: $29.18
Upside: +88.52%
Zimmer Biomet Holdings
Jan 28, 2026
Maintains: Sell
Price Target: $88 → $86
Current: $87.87
Upside: -2.13%
Edwards Lifesciences
Jan 12, 2026
Maintains: Neutral
Price Target: $92 → $95
Current: $82.50
Upside: +15.15%
Inspire Medical Systems
Dec 23, 2025
Maintains: Neutral
Price Target: $89 → $91
Current: $53.72
Upside: +69.40%
Glaukos
Dec 23, 2025
Maintains: Buy
Price Target: $140 → $145
Current: $100.99
Upside: +43.58%
Dec 12, 2025
Initiates: Buy
Price Target: $62
Current: $25.79
Upside: +140.40%
Nov 19, 2025
Maintains: Neutral
Price Target: $95 → $102
Current: $86.16
Upside: +18.38%
Nov 19, 2025
Upgrades: Buy
Price Target: $355 → $400
Current: $227.10
Upside: +76.13%
Nov 7, 2025
Maintains: Neutral
Price Target: $6.5 → $5.85
Current: $1.24
Upside: +371.77%
Nov 6, 2025
Maintains: Neutral
Price Target: $16 → $16
Current: $13.53
Upside: +18.26%
Nov 3, 2025
Maintains: Buy
Price Target: $106 → $95
Current: $66.95
Upside: +41.90%
Oct 31, 2025
Maintains: Neutral
Price Target: $24 → $21
Current: $16.15
Upside: +30.03%
Oct 23, 2025
Maintains: Neutral
Price Target: $585 → $600
Current: $477.97
Upside: +25.53%
Oct 14, 2025
Maintains: Buy
Price Target: $190 → $214
Current: $235.37
Upside: -9.08%
Aug 8, 2025
Maintains: Buy
Price Target: $65 → $57
Current: $21.85
Upside: +160.87%
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $105.46
Upside: +40.34%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $3.97
Upside: -43.32%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $3.36
Upside: +24,453.57%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $30.78
Upside: -54.52%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $76.43
Upside: +30.84%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $13.00
Upside: -7.69%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $31.41
Upside: +43.27%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $154.13
Upside: +78.42%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.39
Upside: +736.82%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.10
Upside: +588.52%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $60
Current: $6.48
Upside: +825.93%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.66
Upside: +2,172.73%